Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Balzarini

Showing results (11-20 of 1,584) with videos related to

Pageof 159
Sort By:
Biochemical Pharmacology|July 14, 1999
Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapyJ Balzarini
Antiviral Research|March 30, 2006
Inhibition of HIV entry by carbohydrate-binding proteinsJ Balzarini
FEBS Letters|May 4, 2007
The alpha(1,2)-mannosidase I inhibitor 1-deoxymannojirimycin potentiates the antiviral activity of carbohydrate-binding agents against wild-type and mutant HIV-1 strains containing glycan deletions in gp120Jan Balzarini
The Journal of Antimicrobial Chemotherapy|July 4, 2002
Bicyclic pyrimidine nucleoside analogues (BCNAs) as highly selective and potent inhibitors of varicella-zoster virus replicationJan Balzarini, Christopher McGuigan
Expert Opinion on Therapeutic Targets|July 17, 2015
The role of cellular oxidoreductases in viral entry and virus infection-associated oxidative stress: potential therapeutic applicationsLeen Mathys, Jan Balzarini
The Journal of Antimicrobial Chemotherapy|August 15, 2009
FV100 as a new approach for the possible treatment of varicella-zoster virus infectionChristopher McGuigan, Jan Balzarini
Magnetic Resonance Imaging|January 1, 1996
NMR study of the diffusion processes in gelsL Pavesi, M Balzarini
Biochimica Et Biophysica Acta|June 27, 2002
Chemotherapy of varicella-zoster virus by a novel class of highly specific anti-VZV bicyclic pyrimidine nucleosidesJ Balzarini, C McGuigan
Delaware Medical Journal|March 18, 1999
An overview of cerebral aneurysms. Which factors affect the outcome of microsurgical treatmentB Bose, M Balzarini
The Journal of Antimicrobial Chemotherapy|October 23, 2013
Exposure of HIV-1 to a combination of two carbohydrate-binding agents markedly delays drug resistance development and selects for virus strains with compromised fitnessLeen Mathys, Jan Balzarini
Pageof 159

Showing results (11-20 of 1,584) with videos related to

Sort By:
Pageof 159
Biochemical Pharmacology|July 14, 1999
Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapyJ Balzarini
Antiviral Research|March 30, 2006
Inhibition of HIV entry by carbohydrate-binding proteinsJ Balzarini
FEBS Letters|May 4, 2007
The alpha(1,2)-mannosidase I inhibitor 1-deoxymannojirimycin potentiates the antiviral activity of carbohydrate-binding agents against wild-type and mutant HIV-1 strains containing glycan deletions in gp120Jan Balzarini
The Journal of Antimicrobial Chemotherapy|July 4, 2002
Bicyclic pyrimidine nucleoside analogues (BCNAs) as highly selective and potent inhibitors of varicella-zoster virus replicationJan Balzarini, Christopher McGuigan
Expert Opinion on Therapeutic Targets|July 17, 2015
The role of cellular oxidoreductases in viral entry and virus infection-associated oxidative stress: potential therapeutic applicationsLeen Mathys, Jan Balzarini
The Journal of Antimicrobial Chemotherapy|August 15, 2009
FV100 as a new approach for the possible treatment of varicella-zoster virus infectionChristopher McGuigan, Jan Balzarini
Magnetic Resonance Imaging|January 1, 1996
NMR study of the diffusion processes in gelsL Pavesi, M Balzarini
Biochimica Et Biophysica Acta|June 27, 2002
Chemotherapy of varicella-zoster virus by a novel class of highly specific anti-VZV bicyclic pyrimidine nucleosidesJ Balzarini, C McGuigan
Delaware Medical Journal|March 18, 1999
An overview of cerebral aneurysms. Which factors affect the outcome of microsurgical treatmentB Bose, M Balzarini
The Journal of Antimicrobial Chemotherapy|October 23, 2013
Exposure of HIV-1 to a combination of two carbohydrate-binding agents markedly delays drug resistance development and selects for virus strains with compromised fitnessLeen Mathys, Jan Balzarini
Pageof 159